Proteostasis Therapeutics (NASDAQ:PTI) changed -0.74% to recent value of $1.34. The stock transacted 1046121 shares during most recent day however it has an average volume of 4.69M shares. It spotted trading -71.61% off 52-week high price. On the other end, the stock has been noted 119.67% away from the low price over the last 52-weeks.
On March 10, 2020, Proteostasis Therapeutics (NASDAQ:PTI) a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) through theratyping, revealed financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.
Proteostasis made important progress throughout 2019 in delivering on our goal of bringing more treatment choices to patients with CF, said Meenu Chhabra, President and Chief Executive Officer of Proteostasis Therapeutics. With our Phase 2 trials complete, we are moving forward with a Phase 3 clinical development plan that embraces the pursuit of personalized medicine in CF through theratyping. Our mission is to deliver combinations of our investigational agents to preselected patients identified as responders to our therapies through the ex vivo testing of their own organoids. We believe that the theratyping path, or the process of matching CFTR modulators to individual CF patients based on a laboratory assay regardless of CFTR genotype, has the potential to become a patient-friendly and cost-effective approach to treatment for patients with CF, thereby increasing access to treatment options and optimizing risk-benefit and cost-effectiveness of CFTR modulators.
Its earnings per share (EPS) expected to touch remained 31.30% for this year.
The company has 52.79M of outstanding shares and 41.38M shares were floated in the market. According to the most recent quarter its current ratio was 6.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of -20.07% from the mean of 20 days, -27.35% from mean of 50 days SMA and performed 0.52% from mean of 200 days price. Company’s performance for the week was -19.28%, -20.71% for month and YTD performance remained -41.23%.